Characterization of C3 in C3 glomerulopathy

被引:41
|
作者
Sethi, Sanjeev [1 ]
Vrana, Julie A. [1 ]
Fervenza, Fernando C. [2 ]
Theis, Jason D. [1 ]
Sethi, Amit [3 ]
Kurtin, Paul J. [1 ]
Zhang, Yuzhou [4 ,5 ]
Smith, Richard J. H. [4 ,5 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA
[3] Mayo High Sch, Rochester, MN USA
[4] Carver Coll Med, Dept Internal Med, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
[5] Carver Coll Med, Dept Pediat, Div Nephrol, Mol Otolaryngol & Renal Res Labs, Iowa City, IA 52242 USA
关键词
C3; glomerulonephritis; glomerulopathy; C3dg; complement; dense deposit disease; HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; MASS-SPECTRAL DATA; ALTERNATIVE PATHWAY; SEQUENCE DATABASES; COMPLEMENT; GLOMERULONEPHRITIS; DYSFUNCTION; PROTEOMICS;
D O I
10.1093/ndt/gfw290
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3a and C3b), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3a (C3a1 and a2), and C3b that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3a (C3a1 and a2) and C3b. Amino acids mapping to C3a and C3f are absent. Taken together, the C3a and C3b amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the generation of iC3b. After additional cleavages, mostly C3dg remains.
引用
收藏
页码:459 / 465
页数:7
相关论文
共 50 条
  • [21] A clinical approach to children with C3 glomerulopathy
    Vivarelli, Marina
    van de Kar, Nicole
    Labbadia, Raffaella
    Diomedi-Camassei, Francesca
    Thurman, Joshua M.
    PEDIATRIC NEPHROLOGY, 2022, 37 (03) : 521 - 535
  • [22] C3 Glomerulopathy: Novel Treatment Paradigms
    Estebanez, Blanca Tarragon
    Bomback, Andrew S.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (03): : 569 - 579
  • [23] Membranoproliferative glomerulonephritis and C3 glomerulopathy
    Hohenstein, B.
    Amann, K.
    Menne, J.
    INTERNIST, 2019, 60 (05): : 458 - 467
  • [24] Remissions and progression of C3 glomerulopathy
    Karunnaya, Anna, V
    Dobronravov, Vladimir A.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (06) : 718 - 724
  • [25] C4 Nephritic Factors in C3 Glomerulopathy: A Case Series
    Zhang, Yuzhou
    Meyer, Nicole C.
    Fervenza, Fernando C.
    Lau, Winnie
    Keenan, Adam
    Cara-Fuentes, Gabriel
    Shao, Dingwu
    Akber, Aalia
    Fremeaux-Bacchi, Veronique
    Sethi, Sanjeev
    Nester, Carla M.
    Smith, Richard J. H.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 70 (06) : 834 - 843
  • [26] State of the art: C3 glomerulopathy and membranoproliferative glomerulonephritis: A consensus
    Hohenstein B.
    Licht C.
    Wiesener M.
    Amann K.
    Schaefer F.
    Serka C.
    Bergmann C.
    Kirschfink M.
    Zipfel P.
    Hugo C.
    Der Nephrologe, 2015, 10 (4): : 327 - 340
  • [27] Eculizumab and recurrent C3 glomerulonephritis
    Gurkan, Sevgi
    Fyfe, Billie
    Weiss, Lynne
    Xiao, Xue
    Zhang, Yuzhou
    Smith, Richard J.
    PEDIATRIC NEPHROLOGY, 2013, 28 (10) : 1975 - 1981
  • [28] Diagnosis and treatment of C3 glomerulopathy in a center of expertise
    Koopman, J. J. E.
    Teng, Y. K. O.
    Boon, C. J. F.
    van den Heuvel, L. P.
    Rabelink, T. J.
    van Kooten, C.
    de Vries, A. P. J.
    NETHERLANDS JOURNAL OF MEDICINE, 2019, 77 (01) : 10 - 18
  • [29] Genetic analysis of the complement pathway in C3 glomerulopathy
    Zhao, Weiwei
    Ding, Yin
    Lu, Jianping
    Zhang, Tao
    Chen, Dacheng
    Zhang, Haitao
    Zeng, Caihong
    Liu, Zhihong
    Chen, Huimei
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (11) : 1919 - 1927
  • [30] von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study
    Chen, Yun-ying
    Han, Sha-sha
    Cao, Yang
    Yu, Xiao-juan
    Zhu, Li
    Luo, Jin-cai
    Song, Wen-chao
    Yu, Feng
    Mao, Yong-hui
    Zhao, Ming-hui
    CLINICAL IMMUNOLOGY, 2021, 229